ALT | alanine aminotransferase = alanine transaminase = glutamic pyruvic transaminase (GPT) |
ANA | antinuclear antibody |
ALP | alkaline phosphatase |
AST | aspartate aminotransferase = aspartate transaminase = glutamic oxalic transaminase (GOT) |
BRCA | breast cancer susceptibility alleles |
CS | corticosteroid |
CS Tx | corticosteroid therapy |
CTCAE CPIH |
Common Terminology Criteria for Adverse Events Check point inhibitor hepatotoxicity |
CTLA-4- cytotoxic T | lymphocytes associated antigen 4 |
DC Dx |
dendritic cells Dexametasone |
DILI | drug-induced liver injury |
DILIN | drug-induced liver injury network |
dMMR | microscope set microsatellite instability high or mismatch repair deficiency |
ECM | extracellular matrix |
EMA | European Medicines Agency |
FDA | United States Food and Drug Administration |
FGF | fibroblast growth factor |
FGFR | fibroblast growth factor signaling pathway |
FISH | Fluorescence In-Situ Hybridization |
GI | Gastrointestinal |
GLDH | glutamate dehydrogenase |
GGT | gamma-glutamyl-transferase |
HER2 | Human estrogen receptor 2 |
HMGB1 | High-mobility group box 1 |
ICI | immune checkpoint inhibitor |
ICOS | Inducible T-cell co-stimulator |
IL | Interleukin |
ICH | Immuno-Histochemistry |
IFN-γ | interferon-gamma |
KIR2DS2 | Killer cell immunoglobulin-like receptor |
LFT | liver function test |
LY403200 | hepatitis A virus cellular receptor 2 (HAVCR2) |
M-CSFR | macrophage colony-stimulating factor |
MMF | Mycophenolate |
MYC | Oncogene c-MYC |
p53 | tumor suppressor protein 53 |
PD-1 | programmed cell death receptor 1 |
PDL-1 | programmed cell death ligand 1 |
PDL- 2 | programmed cell death ligand 2 |
PIK3CA | protein IK3 oncogene |
PTEN | Phosphatase and Tensin Homolog deleted on Chromosome 10 |
RANTES | Regulated upon Activation, Normal T cell Expressed and presumably Secreted |
RUCAM | Roussel Uclaf Causality Assessment Method |
TBL | total bilirubin |
TGF- β | transforming growth factor β |
TIM 3 | T-cell immunoglobulin and mucin domain 3 (Tim-3) encoded in germline mutations in HAVCR2 |
TME | tumor microenvironment |
TNF-α | Tumor necrosis factor alpha |
TNFRSF18 | Tumor necrosis factor receptor superfamily member 18 |
Tx | Therapeutic agent |
UDCA | urso-deoxycholic acid |
ULN | upper limit of normal |
VEGF | vascular endothelial growth factor. |